A dynamic COVID-19 immune signature includes associations with poor prognosis.
Nat Med
; 26(10): 1623-1635, 2020 10.
Article
in English
| MEDLINE | ID: covidwho-717130
ABSTRACT
Improved understanding and management of COVID-19, a potentially life-threatening disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end, we have identified a core peripheral blood immune signature across 63 hospital-treated patients with COVID-19 who were otherwise highly heterogeneous. The signature includes discrete changes in B and myelomonocytic cell composition, profoundly altered T cell phenotypes, selective cytokine/chemokine upregulation and SARS-CoV-2-specific antibodies. Some signature traits identify links with other settings of immunoprotection and immunopathology; others, including basophil and plasmacytoid dendritic cell depletion, correlate strongly with disease severity; while a third set of traits, including a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progression. Hence, contingent upon independent validation in other COVID-19 cohorts, individual traits within this signature may collectively and individually guide treatment options; offer insights into COVID-19 pathogenesis; and aid early, risk-based patient stratification that is particularly beneficial in phasic diseases such as COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Dendritic Cells
/
B-Lymphocytes
/
T-Lymphocytes
/
Cytokines
/
Coronavirus Infections
/
Antibodies, Viral
Type of study:
Cohort study
/
Etiology study
/
Observational study
/
Prognostic study
Language:
English
Journal:
Nat Med
Journal subject:
Molecular Biology
/
Medicine
Year:
2020
Document Type:
Article
Affiliation country:
S41591-020-1038-6
Similar
MEDLINE
...
LILACS
LIS